CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: MEK could also be a potential therapeutic target, as its specific MEK inhibitor PD184352, when combined with BMS-214662 increased apoptosis in TKI-unresponsive CD34+ CML cells [61].